Advice
Following an abbreviated submission
tacrolimus prolonged-release capsule (Advagraf®) is accepted for use within NHS Scotland for prophylaxis of transplant rejection in adult kidney or liver allograft recipients and treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.
It is suitable for use by patients for whom tacrolimus is an appropriate choice of immunosuppressive therapy. It has similar costs per equivalent dose to the tacrolimus immediate release capsule.
Download detailed advice30KB (PDF)
Medicine details
- Medicine name:
- tacrolimus 0.5mg, 1mg, 5mg prolonged release capsule (Advagraf)
- SMC ID:
- 402/07
- Indication:
- for prophylaxis of transplant rejection in adult kidney or liver allograft recipients and allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients
- Pharmaceutical company
- Astellas Pharma Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 10 September 2007